CMS Proposes 15% Medicare Lab Fee Cuts, Impacting Labcorp and Quest Diagnostics
The Centers for Medicare & Medicaid Services (CMS) is targeting a 15% reduction in Medicare lab fees. This proposed cut is expected to put revenue at risk for major diagnostic companies like Labcorp and Quest Diagnostics, leading to a decline in their stock prices.
3 articles from 1 outlet covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
1 outlet covered “CMS Proposes 15% Medicare Lab Fee Cuts, Impacting Labcorp and Quest Diagnostics”. All of them report the following:
- CMS targets Medicare lab fee cuts
- Proposed cuts are 15%
- Labcorp (LH) revenue at risk
- Quest Diagnostics (DGX) revenue at risk
- Labcorp stock is sliding
- Quest Diagnostics stock is sliding
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.
pragmatist3